What C80 covers · when clinicians use it
ICD-10 code C80 identifies Malignant neoplasm without specification of site in the U.S. ICD-10-CM clinical and billing record set. It sits within the Neoplasms chapter (C00–D49), the section that groups related diagnoses so providers, payers, and public-health agencies report them consistently. Clinicians and medical coders apply C80 when an encounter's findings match the Malignant neoplasm without specification of site description, attaching it to the patient record so downstream insurance claims, payer audits, quality reporting, and epidemiological surveillance all reference the same standardized diagnosis. The ICD-10-CM is maintained by the Centers for Medicare & Medicaid Services and the CDC's National Center for Health Statistics, with an updated official code set released each U.S. fiscal year — always verify C80 against the current CMS/CDC release and your payer's documentation guidance before final use. This page summarizes documentation context for C80 and is a coding reference, not clinical, diagnostic, or billing advice.
C80 refers to Malignant neoplasm without specification of site, a group of ICD10 codes used to describe metastatic or unspecified cancer diagnoses when the origin or site is either unknown or not clearly defined. These codes are crucial for documenting cancer staging, treatment of secondary malignancies, and palliative care management.
Symptoms
- Persistent unexplained pain – Often at metastatic sites
- Swelling or lumps – Especially in lymph nodes or soft tissues
- Weight loss and fatigue – General signs of advanced disease
- Cough or difficulty breathing – May occur with pulmonary metastases
- Liver enlargement or jaundice – From digestive organ spread
- Neurological changes – Suggestive of brain or spinal metastases
- Site-specific symptoms – Depending on the location of metastasis
Diagnosis
Diagnosis of Malignant neoplasm without specification of site typically follows initial cancer identification or when cancer presents without a known primary source. Imaging (CT, PET, MRI), biopsy, and tumor marker studies are used to evaluate the extent of disease and potential origin. These codes help classify the cancer stage and inform prognosis and treatment planning.
ICD10 Code Usage
ICD10 code C80 is widely used in oncology to document metastases and unspecified malignancies. It is essential for insurance claims, hospice and palliative care coding, cancer registry updates, and clinical trial stratification when a primary tumor site is not confirmed.
Related Codes
- C76 – Malignant neoplasm of other and ill-defined sites
- C77 – Secondary and unspecified malignant neoplasm of lymph nodes
- C78 – Secondary malignant neoplasm of respiratory and digestive organs
- C79 – Secondary malignant neoplasm of other and unspecified sites
FAQs
Q1: What is ICD10 code C80?
A: This code is used to document Malignant neoplasm without specification of site, often related to metastatic or site-unknown cancers.
Q2: When is this code used?
A: It’s used when cancer spreads from its original site or when the primary tumor cannot be identified.
Q3: Is this a final diagnosis?
A: Often, yes—particularly in metastatic disease. It may also be provisional until the primary site is found.
Q4: How is metastatic cancer treated?
A: Treatment focuses on systemic therapies like chemotherapy, immunotherapy, and palliative care.
Q5: Why is ICD coding important in cancer?
A: It helps track disease progression, supports clinical decisions, and facilitates insurance reimbursement.
Conclusion
ICD10 code C80 is critical for accurately documenting Malignant neoplasm without specification of site. It supports cancer treatment workflows, facilitates reporting and epidemiologic tracking, and ensures appropriate care delivery for advanced-stage patients. Proper usage improves outcomes, even in cases where the primary cancer site is unknown.